Chromium in metabolic and cardiovascular disease

Hormone and Metabolic Research

Volumn 39, Issue 10, 2007, Pages 743-751

  Hummel, M ^a   Standl, E ^a   Schnell, O ^a  

^a Klinikum Schwabing   (Germany)

Author keywords

Cardiovascular risk; Chromium; Chromium picolinate; Diabetes; Insulin; Metabolic syndrome

Indexed keywords

CHROMIUM; CHROMIUM CHLORIDE; CHROMIUM NICOTINATE; CHROMIUM PICOLINATE; PLACEBO; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DIETARY INTAKE; DRUG ABSORPTION; DRUG MECHANISM; GLUCOSE INTAKE; GLUCOSE TOLERANCE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; META ANALYSIS; METABOLIC SYNDROME X; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; CHROMIUM; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; HUMANS; INSULIN; METABOLIC DISEASES; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; NUTRITIONAL REQUIREMENTS; RISK FACTORS;

EID: 36048971454     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-985847     Document Type: Conference Paper

References (69)

1. Food and Nutrition Board. Recommended dietary allowances 10th ed. Washington, DC: National Academy Press, 2000
2. Anderson RA. Chromium, glucose intolerance and diabetes. J Am Coll Nutr 1998; 17: 548-555
3. Jeejeebhoy KN, Chu RC, Marliss EB, Greenberg GR, Bruce-Robertson A. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr 1977; 30: 531-538
4. Freund H, Atamian S, Fischer JE. Chromium deficiency during total parenteral nutrition. JAMA 1979; 241: 496-498
5. Brown RO, Forloines-Lynn S, Cross RE, Heizer WD. Chromium deficiency after long-term total parenteral nutrition. Dig Dis Sci 1986; 31: 661-664
6. Anderson RA. Chromium and parenteral nutrition. Nutrition 1995; 11: 83-86
7. Nielsen F. Controversial chromium: does the superstar mineral of the mountebanks receive appropriate attention from clinicians and nutritionists? Nutr Today 1996; 31: 226-233
8. Anderson R, Cheng N, Bryden N et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997; 46: 1786-1791
9. Anderson RA. Nutritional factors influencing the glucose/insulin system: chromium. J Am Coll Nutr 1997; 16: 404-410
10. Vincent JB. Elucidating a biological role for chromium at a molecular level. Acc Chem Res 2000; 33: 503-510
11. Anderson RA, Polansky MM, Bryden NA. Stability and absorption of chromium and adsorption of chromium histidinate complexes by humans. Biol Trace Elem Res 2004; 101: 211-218
12. Anderson RA, Bryden NA, Evock-Clover M, Steele NC. Beneficial effects of chromium on glucose and lipid variables in control and somatotropin-treated pigs are associated with increased tissiue chromium and altered tissiue copper, iron, and zinc. J Anim Sci 1997; 75: 657-661
13. Anderson RA, Bryden NA, Polansky MM, Gautschl K. Dieatary chromium effects on tissue chromium concentrations and chromium absorption in rats. J Trace Elem Exp Med 1996; 9: 12-25
14. Rajpathak S, Rimm EB, Li T, Morris JS, Stampfer MJ, Willett WC, Hu FB. Lower toenail chromium in men with diabetes and cardiovascular disease compared with healthy men. Diabetes Care 2004; 27: 2211-2216
15. Doisy RJ, Streeten DHP, Freiberg JM, Schneider AJ. Chromium metabolism in man and biochemical effects. In: Prasad AS, Oberleas D (eds). Trace Elements in Human Health and Disease: Essential and Toxic Elements Vol. 2. New York: Marcel Dekker, 1976
16. Bunker VW, Lawson MS, Delves HT, Clayton BE. The uptake and excretion of chromium in the elderly. Am J Clin Nutr 1984; 39: 797-802
17. Saad MJA. Molecular mechanisms of insulin resistance. Braz J Med Biol Res 1994; 27: 941-957
18. Kahn CR. Current concepts of the molecular mechanism of insulin action. Ann Rev Med 1985; 36: 429-451
19. Roth RA, Lui F, Chin JE. Biochemical mechanisms of insulin resistance. Horm Res 1994; 41 (Suppl 2): 51-55
20. Davis CM, Vincent JB. Chromium oligopeptide activates insulin receptor kinase activity. Biochemistry 1997; 36: 4382-4385
21. Vincent JB. The quest for the molecular mechanism of chromium action and its relationship to diabetes. Nutr Rev 2000; 58
22. Yamamoto A, Wada O, Ono T. Isolation of a biologically active low-molecular-mass chromium compound from rabbit liver. Eur J Biochem 1987; 165: 627-631
23. Davis CM, Vincent JB. Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochemistry 1997; 36: 4382-4385
24. Rabinowitz MB, Gonick HC, Levine SR, Davidson MB. Clinical trial of chromium and yeast supplements on carbohydrate and lipid metabolism in diabetic men. Biol Trace Elem Res 1983; 5: 449-466
25. Uusitupa MIJ, Kumpulainen JT, Voutilainen E, Hersio K, Sarlund H, Pyorala KP, Koivistoinen P, Lehto JT. Effect of inorganic chromium supplementation on glucose tolerance, insulin response and serum lipids in noninsulin-dependent diabetics. Am J Clin Nutr 1983; 38: 404-410
26. Mossop RT. Effects of chromium (III) on fasting glucose, cholesterol and cholesterol HDL levels in diabetics. Cent Afr J Med 1983; 29: 80-82
27. Nath R, Minocha J, Lyall V, Sunder S, Kumar V, Kapoor S, Dhar KL. Assessment of chromium metabolism in maturity onset and juvenile diabetes using chromium-51 and therapeutic response of chromium administration on plasma lipids, glucose tolerance and insulin levels. In Shapcott D, Hubert J (eds): Chromium in Nutrition and Metabolism. Amsterdam: Elsevier/North Holland, 1979; 213-222
28. Wang ZQ, Zhang XH, Russell JC, Hulver M, Cefalu WT. Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. J Nutr 2006; 136: 415-420
29. Chen G, Liu P, Pattar GR, Tackett L, Bhonagiri P, Strawbridge AB, Elmendorf JS. Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. Mol Endocrinol 2006; 20: 857-870
30. Pattar GR, Tackett L, Liu P, Elmendorf JS. Chromium picolinate positively influences the glucose transporter system via affecting cholesterol homeostasis in adipocytes cultured under hyperglycemic diabetic conditions. Mutat Res 2006; 610: 93-100
31. Glinsmann W, Mertz W. Effect of trivalent chromium on glucose tolerance. Metabolism 1966; 15: 510-520
32. Sherman L, Glennon JA, Brech WJ, Klomberg GH, Gordon ES. Failure of trivalent chromium to improve hyperaglycemia in diabetes mellitus. Metabolism 1968; 17: 439-442
33. Offenbacher KG, Pi-Sunyer X. Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects. Diabetes 1980; 29: 919-925
34. Elias AN, Grossman MK, Valenta LJ. Use of the artificial beta cell (ABC) in the assessment of peripheral insulin sensitivity; effect of chromium supplementation in diabetic patients. Gen Pharmacol 1984; 15: 535-539
35. Evans GW. The effect of chromium picolinate on insulin controlled parameters in humans. Int J Biosoc Med Res 1989; 11: 163-180
36. Roeback Jr JR, Mae K, Chambless LE, Fletcher RH. Effects of chromium supplementation on serum high-density lipoprotein cholesterol levels in men taking beta-blockers. Ann Intern Med 1991; 115: 917-924
37. Abraham AS, Brooks BA, Eylath U. The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes. Metabolism 1992; 41: 768-771
38. Lee NA, Reasner CA. Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM. Diabetes Care 1994; 17: 1449-1452
39. Ravina A, Slezak L, Rubal A, Mirsky N. Clinical use of the trace element chromium (III) in the treatment of diabetes mellitus. J Trace Elem Exp Med 1995; 8: 183-190
40. Jovanovic-Peterson L, Gutierry M, Peterson CM. Chromium supplementation for gestational diabetic women (GDM) improves glucose tolerance and decreases hyperinsulinemia. Diabetes 1996; 43: 337
41. Thomas VLK, Gropper SS. Effect of chromium nicotinic acid supplementation on selected cardiovascular disease risk factors. Biol Trace Elem Res 1997; 55: 297-305
42. Anderson RA, Cheng N, Bryden NA, Polansky MM, Chi J, Feng J. Beneficial effects of chromium for people with diabetes. Diabetes 1997; 46: 1786-1791
43. Ravina A, Slezak L, Mirsky N, Bryden NA, Anderson RA. Reversal of corticosteroid-induced diabetes mellitus with supplemental chromium. Diabet Med 1999; 16: 164-167
44. Cheng N, Zhu X, Shi H, Wu W, Chi J, Cheng J, Anderson R. Follow-up survey of people in China with type 2 diabetes mellitus consuming supplemental chromium. J Trace Elem Exp Med 1999; 12: 55-60
45. Cefalu WT, Bell-Farrow AD, Stegner J, Wang ZQ, King T, Morgan T, Terry JG. Effect of chromium picolinate on insulin sensitivity in vivo. J Trace Elem Exp Med 1999; 12: 71-83
46. Trow LG, Lewis J, Greenwood RH, Sampson MJ, Self KA, Crews HM, Fairweather-Tait SJ. Lack of effect of dietary chromium supplementation on glucose tolerance, plasma insulin and lipoprotein levels in patients with type 2 diabetes. Int J Vitam Nutr Res 2000; 70: 14-18
47. Morris BW, Kouta S, Robinson R, MacNeil S, Heller S. Chromium supplementation improves insulin resistance in patients with type 2 diabetes mellitus. Diabet Med 2000; 17: 684-685
48. Ghosh D, Bhattacharya B, Mukherjee B, Manna B, Sinha M, Chowdhury J, Showdhury S. Role of chromium supplementation in Indians with type 2 diabetes mellitus. J Nutr Biochem 2002; 13: 690-697
49. Gunton JE, Cheung NW, Hitchman R, Hams G, O'Sullivan C, Foster-Powell K, MacElduff A. Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance. Diabetes Care 2005; 28: 712-713
50. Kleefstra N, Houweling ST, Jansman FG, Groenier KH, Gans RO, Meyboom-de Jong B, Bakker SJ, Bilo HJ. Chromium treatment has no Effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese western population. A randomized, double-blind, placebo-controlled trial. Diabetes Care 2006; 29: 521-525
51. Vrtovec M, Vrtovec B, Briski A, Kocijancic A, Anderson RA, Radovancevic B. Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus. Am Heart J 2005; 149: 632-635
52. Martin J, Wang ZQ, Zhang XH et al. Chormium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 2006; 29: 1826-1832
53. Bahijri SM, Mira SA, Mufti AM, Ajabnoor MA. The effects of inorganic chromium and brewer's yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with type 2 diabetes. Saudi Med J 2000; 21: 831-837
54. Bahijri SM, Mufti AM. Beneficial effects of chromium in people with type 2 diabetes, and urinary chromium response to glucose load as a possible indicator of status. Biol Trace Elem Res 2002; 85: 97-109
55. Komorowski J, Juturu V. Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance. Response to Gunton et al. Diabetes Care 2005; 28: 1841-1842
56. Althuis MD, Jordan NE, Ludington EA, Wittes JT. Glucose and insulin responses to dietary chromium supplements: a meta-analysis. Am J Clin Nutr 2002; 76: 148-155
57. Pittler MH, Stevinson C, Ernst E. Chromium picolinate for reducing body weight: meta-analysis of randomized trials. Int J Obes Relat Metab Disord 2003; 27: 522-529
58. Uusitupa MI, Mykkanen L, Siitonen O, Laakso M, Sarlund H, Kolehmainen P, Rasanen T, Kumpulainen J, Pyorala K. Chromium supplementation in impaired glucose tolerance of elderly: effects on blood glucose, plasma insulin, C-peptide and lipid levels. Br J Nutr 1992; 68: 209-216
59. Volpe SL, Huang HW, Larpadisorn K, Lesser II. Effect of chromium supplementation and exercise on body composition, resting metabolic rate and selected biochemical parameters in moderately obese women following an exercise program. J Am Coll Nutr 2001; 20: 293-306
60. Cefalu WT, Hu FB. Role of chromium in human health and in diabetes. Diabetes Care 2004; 27: 2741-2751
61. Anderson RA. Chromium, glucose tolerance, diabetes and lipid metabolism. J Adv Med 1995; 8: 37-49
62. Kaats GR, Keith SC, Wise JA, Pullin D, Squires WG. Effects of baseline total cholesterol levels on diet and exercise interventions. JANA 1999; 2: 42-49
63. Boyd SG, Boone BE, Smith AR, Conners J, Dohm GL. Combined dietary chromium picolinate supplementation and an exercise program leads to a reduction of serum cholesterol and insulin in college-aged subjects. J Nutr Biochem 1998; 9: 471-475
64. Press RI, Geller J, Evans GW. The effect of chromium picolinate on serum cholesterol and apolipoprotein fractions in human subjects. West J Med 1990; 152: 41-45
65. Guallar E, Jimenez FJ, Veer P van't, Bode P, Riemersma RA, Gomez-Aracena J, Kark JD, Arab L, Kok FJ, Martin-Moreno JM, EURAMIC-Heavy Metals and Myocardial Infarction Study Group. Low toenail chromium concentration and increased risk of nonfatal myocardial infarction. Am J Epidemiol 2005; 162: 157-164
66. Jain SK, Patel P, Rogier K, Jain SK. Trivalent chromium inhibits protein glycosylation and lipid peroxidation in high glucose-treated erythrocytes. Antioxid Redox Signal 2006; 8: 238-241
67. American Diabetes Association. Standards of medical care in diabetes (Position Statement). Diabetes Care 2006; 29 (Suppl 1): 14
68. Vincent JB. The Biochemistry of Chromium. J Nutr 2000; 130: 715-718
69. http://www.cfsan.fda.gov/~dms/qhccr.html